BofA raised the firm’s price target on Johnson & Johnson to $220 from $204 and keeps a Neutral rating on the shares. The firm, which believes J&J’s premium-sector multiple “looks appropriate for its growth plus asset mix,” is shifting its valuation basis to its new FY27 EPS estimate.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Balanced Risk-Reward Profile for Johnson & Johnson Amid Limited Stock Re-Rating Potential
- Johnson & Johnson announces FDA approved sNDA for AKEEGA plus prednisone
- FDA approves J&J’s Akeega BRCA2-mutated prostate cancer
- Johnson & Johnson price target raised to $197 from $190 at Morgan Stanley
- Johnson & Johnson price target raised to $230 from $209 at RBC Capital